MedElevator Войти в исследования
← Поиск публикаций

DOI 10.36660/abc.20260069

Медицинская библиотека · Arquivos brasileiros de cardiologia · 2026

Sacubitril/Valsartan versus Enalapril or Losartan at Maximum Doses in Heart Failure with Reduced Ejection Fraction: Real-World Data.

Barros Renato de Carvalho, Fiusa Vinícius C, Tim Gabrielle N, Goulart Victoria T V, Nascimento Caio Henrique M, Moura Gustavo T de, Guimarães Adriana J B A, Ramalho Sergio Henrique Rodolpho, Jreige Armindo, Moura Filipe A, Carvalho Luiz Sérgio Fernandes de

СтатьяСравнительное исследованиеНаблюдательное исследованиеПеревод в очереди

Аннотация

BACKGROUND

Sacubitril/valsartan reduced mortality and hospitalizations in patients with heart failure with reduced ejection fraction (HFrEF) compared to enalapril in pivotal clinical trials. However, real-world data under optimized dosing remain limited.

OBJECTIVE

To compare the outcomes of HFrEF patients treated with sacubitril/valsartan versus either enalapril or losartan at guideline-recommended maximum dosages.

METHODS

We analyzed data from an observational heart failure cohort (n = 2,314) including patients receiving care between August 2010 and September 2024 at six public hospitals in a large metropolitan area. The primary analysis included 254 HFrEF patients receiving the guideline-recommended maximum dosages of the investigated drugs. A sensitivity analysis included 452 patients receiving any submaximal dosages. The primary outcome was combined hospitalization or death. Baseline differences were adjusted using propensity score matching. A p-value < 0.05 was considered significant.

RESULTS

Among 254 HFrEF patients (mean age 63.6 ± 12.3 years, 61.4% male), 115 received sacubitril/valsartan 97/103mg twice daily, 33 enalapril 20 mg twice daily, and 106 losartan 100 mg daily. Over the median follow-up of 23.9 months (interquartile range 11.9-41.1), there were 70 primary endpoint events (56 first hospitalizations, 32 deaths). Compared to equivalent dosages of enalapril or losartan, sacubitril/valsartan was not associated with significant reductions in combined hospitalization or death (odds ratio 0.650, 95% confidence interval 0.354-1.195, p = 0.165), but it was associated with functional status improvement (odds ratio 3.902, 95% confidence interval 1.745-8.726, p = 0.001).

CONCLUSION

This real-world study did not demonstrate significant reductions in hospitalization or mortality for sacubitril/valsartan compared with enalapril or losartan at guideline-recommended maximum dosages; however, sacubitril/valsartan was associated with improved functional status.

Для цитирования: Barros Renato de Carvalho, Fiusa Vinícius C, Tim Gabrielle N, Goulart Victoria T V, Nascimento Caio Henrique M, Moura Gustavo T de, Guimarães Adriana J B A, Ramalho Sergio Henrique Rodolpho, Jreige Armindo, Moura Filipe A, Carvalho Luiz Sérgio Fernandes de. Sacubitril/Valsartan versus Enalapril or Losartan at Maximum Doses in Heart Failure with Reduced Ejection Fraction: Real-World Data.. Arquivos brasileiros de cardiologia. 2026. DOI: 10.36660/abc.20260069.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.